Literature DB >> 17626119

The lethal phenotype of cancer: the molecular basis of death due to malignancy.

Robert D Loberg1, Deborah A Bradley, Scott A Tomlins, Arul M Chinnaiyan, Kenneth J Pienta.   

Abstract

The last decade has seen an explosion in knowledge of the molecular basis and treatment of cancer. The molecular events that define the lethal phenotype of various cancers--the genetic and cellular alterations that lead to a cancer with a poor or incurable prognosis--are being defined. While these studies describe the cellular events of the lethal phenotype of cancer in detail, how these events result in the common clinical syndromes that kill the majority of cancer patients is not well understood. It is clear that the central step that makes most cancers incurable is metastasis. Understanding the traits that a cancer acquires to successfully grow and metastasize to distant sites gives insight into how tumors produce multiple factors that result in multiple different clinical syndromes that are lethal for the patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17626119     DOI: 10.3322/canjclin.57.4.225

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  61 in total

1.  Metabolic signatures imaged in cancer-induced cachexia.

Authors:  Marie-France Penet; Mayur M Gadiya; Balaji Krishnamachary; Sridhar Nimmagadda; Martin G Pomper; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Cancer Res       Date:  2011-09-26       Impact factor: 12.701

Review 2.  Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment.

Authors:  Spiros A Vlahopoulos; Osman Cen; Nina Hengen; James Agan; Maria Moschovi; Elena Critselis; Maria Adamaki; Flora Bacopoulou; John A Copland; Istvan Boldogh; Michael Karin; George P Chrousos
Journal:  Cytokine Growth Factor Rev       Date:  2015-06-20       Impact factor: 7.638

Review 3.  Cancer cachexia, recent advances, and future directions.

Authors:  Marie-France Penet; Zaver M Bhujwalla
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

4.  Disrupting the networks of cancer.

Authors:  Daniel F Camacho; Kenneth J Pienta
Journal:  Clin Cancer Res       Date:  2012-03-22       Impact factor: 12.531

Review 5.  Understanding cancer-induced cachexia: imaging the flame and its fuel.

Authors:  Marie-France Penet; Paul T Winnard; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Curr Opin Support Palliat Care       Date:  2011-12       Impact factor: 2.302

6.  Ten unanswered questions in cancer: "If this is true, what does it imply"?

Authors:  Sarah R Amend; Amber E de Groot; Gonzalo Torga; Haley D Axelrod; Diane K Reyes; Kenneth C Valkenburg; Stephanie A Glavaris; Kenneth J Pienta
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

7.  Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.

Authors:  Joshua R Huot; Leah J Novinger; Fabrizio Pin; Ashok Narasimhan; Teresa A Zimmers; Thomas M O'Connell; Andrea Bonetto
Journal:  JCI Insight       Date:  2020-05-07

8.  CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.

Authors:  Robert D Loberg; Chi Ying; Matt Craig; Li Yan; Linda A Snyder; Kenneth J Pienta
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

9.  The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer.

Authors:  Ozgur Kemik; Aziz Sumer; Ahu Sarbay Kemik; Ismail Hasirci; Sevim Purisa; Ahmet Cumhur Dulger; Baris Demiriz; Sefa Tuzun
Journal:  World J Surg Oncol       Date:  2010-09-28       Impact factor: 2.754

10.  Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.

Authors:  Paola Aulino; Emanuele Berardi; Veronica M Cardillo; Emanuele Rizzuto; Barbara Perniconi; Carla Ramina; Fabrizio Padula; Enrico P Spugnini; Alfonso Baldi; Fabio Faiola; Sergio Adamo; Dario Coletti
Journal:  BMC Cancer       Date:  2010-07-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.